Breaking News

Taiwan Bio, TRACT Therapeutics Complete TregCel Tech Transfer

Advances the companies’ efforts to prepare for a global Phase 2 trial in living donor kidney transplant patients.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Taiwan Bio Therapeutics, Inc. and TRACT Therapeutics, Inc. have successfully transferred TRACT Therapeutics’ regulatory T cell (TregCel) platform technology to Taiwan Bio’s GMP cell manufacturing facility. This milestone advances the companies’ efforts to prepare for the initiation of a global Phase 2 trial in living donor kidney transplant patients seeking new therapeutic options to improve quality of life.   The companies partnered in December 2023 to leverage Taiwan Bio’s expertise in cellu...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters